Payment overview · 2025
General Payments
$1,125.58
45 reported records · 13 companies
Healthcare provider profile · identity verified
Wayne T Richey, MD
Allopathic & Osteopathic Physicians|Family Medicine · TRION, GA · NPI 1073508115
Verified facts
What the public records show
CMS Open Payments records show Wayne T Richey, MD received $1,125.58 in general payments during 2025 across 45 reported records.
Boston Scientific Corporation accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $289.54 | 25.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $174.62 | 15.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.74 | 14.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.20 | 12.9% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.75 | 7.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.91 | 4.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.41 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.51 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.46 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.35 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.50 | 2.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.22 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.37 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,125.58 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $151.91 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.39 | 6 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $110.21 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.72 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.18 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.18 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $88.75 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.15 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $67.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.91 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.52 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.46 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 182 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 625 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 624 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 141 |
| Gabapentin | Gabapentin | 516 | 132 |
| Omeprazole | Omeprazole | 496 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 137 |
| Furosemide | Furosemide | 439 | 124 |
| Diclofenac Sodium | Diclofenac Sodium | 388 | 112 |
| Lisinopril | Lisinopril | 373 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 360 | 105 |
| Montelukast Sodium | Montelukast Sodium | 327 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 90 |
| Carvedilol | Carvedilol | 259 | 68 |
| Famotidine | Famotidine | 258 | 67 |
| Trazodone Hcl | Trazodone Hcl | 256 | 72 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 247 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 245 | 82 |
| Metformin Hcl | Metformin Hcl | 244 | 64 |
| Losartan Potassium | Losartan Potassium | 239 | 73 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 225 | 32 |
| Potassium Chloride | Potassium Chloride | 218 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 217 | 57 |
| Pregabalin | Pregabalin | 214 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 210 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 60 |
| Alprazolam | Alprazolam | 201 | 27 |
| Sertraline Hcl | Sertraline Hcl | 189 | 48 |
| Tramadol Hcl | Tramadol Hcl | 189 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 52 |
| Methylprednisolone | Methylprednisolone | 184 | 112 |
| Eliquis | Apixaban | 182 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 52 |
| Ozempic | Semaglutide | 162 | 26 |
| Allopurinol | Allopurinol | 161 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 57 |
| Metformin Hcl Er | Metformin Hcl | 156 | 36 |
| Buspirone Hcl | Buspirone Hcl | 151 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 40 |
| Lorazepam | Lorazepam | 145 | 28 |
| Spironolactone | Spironolactone | 142 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 44 |
| Meloxicam | Meloxicam | 138 | 47 |
| Glipizide Er | Glipizide | 135 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 34 |
| Methocarbamol | Methocarbamol | 127 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 30 |
| Jardiance | Empagliflozin | 113 | 24 |
| Amoxicillin | Amoxicillin | 112 | 95 |
| Ibuprofen | Ibuprofen | 111 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 36 |
| Prednisone | Prednisone | 101 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | 22 |
| Glimepiride | Glimepiride | 87 | 20 |
| Clonazepam | Clonazepam | 85 | 18 |
| Trulicity | Dulaglutide | 85 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 84 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 19 |
| Atenolol | Atenolol | 82 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 25 |
| Simvastatin | Simvastatin | 82 | 21 |
| Donepezil Hcl | Donepezil Hcl | 80 | 27 |
| Benazepril Hcl | Benazepril Hcl | 77 | 21 |
| Estradiol | Estradiol | 75 | 18 |
| Januvia | Sitagliptin Phosphate | 74 | 13 |
| Meclizine Hcl | Meclizine Hcl | 74 | 28 |
| Memantine Hcl | Memantine Hcl | 74 | 18 |
| Celecoxib | Celecoxib | 70 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 34 |
| Ventolin Hfa | Albuterol Sulfate | 70 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | suppressed |
| Cephalexin | Cephalexin | 61 | 50 |
| Torsemide | Torsemide | 61 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Aripiprazole | Aripiprazole | 57 | 15 |
| Baclofen | Baclofen | 57 | 21 |
| Valsartan | Valsartan | 57 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 37 |
| Levetiracetam | Levetiracetam | 56 | 15 |
| Azithromycin | Azithromycin | 54 | 44 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 15 |
| Fluconazole | Fluconazole | 52 | 33 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Azelastine Hcl | Azelastine Hcl | 47 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Naproxen | Naproxen | 44 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Fenofibrate | Fenofibrate | 43 | 17 |
| Topiramate | Topiramate | 43 | 15 |
| Diazepam | Diazepam | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 19 |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 26 |
| Bupropion Xl | Bupropion Hcl | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Lovastatin | Lovastatin | 39 | 12 |
| Calcitriol | Calcitriol | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Cilostazol | Cilostazol | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 15 |
| Ramipril | Ramipril | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 26 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 12 |
| Xarelto | Rivaroxaban | 25 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Primidone | Primidone | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Caplyta | Lumateperone Tosylate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,125.58 · 45 records | Boston Scientific Corporation | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, BodyGuardian, CDS - MCT/CEM Monitoring, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error